Mental health startup focused on seniors launches with $32M, backing from Arch Venture Partners The news: Rippl, a Seattle startup focused on the mental health of seniors, launched Wednesday with $32 million in seed… Read More
ARCH Venture Partners raises close to $3B for early-stage biotech fund ARCH Venture Partners has closed a $2.975 billion fund targeted for early-stage biotech companies. The firm’s 12th venture fund comes… Read More
Juno’s lasting legacy: How the cell therapy juggernaut influenced biotech in Seattle and beyond When Juno Therapeutics launched in 2013, cell therapy was a nascent field. Early clinical studies were showing dramatic rates of… Read More
Fred Hutch spinout Faraday Pharmaceuticals raises $25M for muscle loss prevention drug When a patient is bedridden during a hospital stay, they can lose muscle mass at a rapid clip, compounding problems… Read More
Seattle startup Rodeo Therapeutics raises more cash for regenerative medicine treatments Seattle-based startup Rodeo Therapeutics is raising more cash for its work on tissue repair and regeneration. The company has reeled… Read More
Former Juno execs unveil Sana, a new cell engineering biotech that’s reportedly raising more than $800M Former Juno Therapeutics executives Hans Bishop and Steve Harr have launched Sana Biotechnology, a startup focused on cell therapy, gene… Read More
Tech Moves: Institute for Systems Biology names president to replace Lee Hood; Seattle VC moves to Silicon Valley; new F5 CEO gets started Seventeen years after founding the Institute for Systems Biology (ISB), spurring the creation of systems biology as a field, genomics… Read More
Seattle biotech investor Robert Nelsen named to Midas List of top performing VCs, propelled by early investment in Juno Robert Nelsen may not be a household name in venture capital circles — certainly not the way that Reid Hoffman,… Read More
